Omnicell, Inc. (NASDAQ:OMCL) Given Average Recommendation of “Hold” by Analysts

Shares of Omnicell, Inc. (NASDAQ:OMCL) have earned an average recommendation of “Hold” from the six research firms that are covering the company, Marketbeat Ratings reports. Four investment analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $52.33.

A number of equities research analysts recently issued reports on OMCL shares. StockNews.com lowered Omnicell from a “buy” rating to a “hold” rating in a research report on Tuesday, December 10th. Wells Fargo & Company lowered their price target on shares of Omnicell from $49.00 to $40.00 and set an “equal weight” rating on the stock in a research note on Monday, January 13th. Benchmark reiterated a “buy” rating and set a $62.00 target price on shares of Omnicell in a report on Tuesday, February 4th. JPMorgan Chase & Co. increased their price target on shares of Omnicell from $37.00 to $44.00 and gave the company a “neutral” rating in a research note on Thursday, November 21st. Finally, Craig Hallum raised their price objective on Omnicell from $45.00 to $64.00 and gave the company a “buy” rating in a research report on Thursday, October 31st.

Insider Buying and Selling

In other Omnicell news, Director Mark W. Parrish sold 12,000 shares of the business’s stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $47.30, for a total value of $567,600.00. Following the completion of the sale, the director now owns 58,427 shares of the company’s stock, valued at $2,763,597.10. The trade was a 17.04 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 2.64% of the stock is owned by insiders.

Institutional Investors Weigh In On Omnicell

A number of hedge funds and other institutional investors have recently made changes to their positions in OMCL. Vanguard Group Inc. boosted its position in shares of Omnicell by 0.5% during the 4th quarter. Vanguard Group Inc. now owns 5,562,165 shares of the company’s stock worth $247,628,000 after acquiring an additional 28,573 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in Omnicell by 31.6% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,642,626 shares of the company’s stock worth $73,127,000 after purchasing an additional 394,820 shares during the last quarter. Victory Capital Management Inc. boosted its holdings in shares of Omnicell by 32.9% in the 4th quarter. Victory Capital Management Inc. now owns 1,526,309 shares of the company’s stock valued at $67,951,000 after purchasing an additional 377,883 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. increased its stake in shares of Omnicell by 93.3% in the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,450,416 shares of the company’s stock valued at $64,573,000 after purchasing an additional 699,925 shares during the last quarter. Finally, ArrowMark Colorado Holdings LLC raised its holdings in shares of Omnicell by 27.1% during the 3rd quarter. ArrowMark Colorado Holdings LLC now owns 1,140,873 shares of the company’s stock worth $49,742,000 after buying an additional 243,353 shares in the last quarter. 97.70% of the stock is currently owned by institutional investors and hedge funds.

Omnicell Stock Down 1.5 %

Omnicell stock opened at $39.61 on Monday. Omnicell has a twelve month low of $25.12 and a twelve month high of $55.74. The company has a quick ratio of 0.95, a current ratio of 1.37 and a debt-to-equity ratio of 0.13. The company has a 50 day moving average of $43.64 and a 200-day moving average of $43.89. The stock has a market capitalization of $1.83 billion, a PE ratio of 146.71, a price-to-earnings-growth ratio of 26.98 and a beta of 0.78.

Omnicell (NASDAQ:OMCL) last announced its earnings results on Thursday, February 6th. The company reported $0.45 earnings per share for the quarter, missing analysts’ consensus estimates of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%. On average, equities research analysts anticipate that Omnicell will post 1.04 EPS for the current fiscal year.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.